
NYSE:STZ
This summary was created by AI, based on 2 opinions in the last 12 months.
Constellation Brands Inc (STZ-N) is set to report earnings insights that highlight mixed perspectives from analysts. One expert expresses optimism, showcasing confidence in the newly appointed CEO and anticipating a positive shift in beer and cocktail sales. Conversely, another expert paints a more negative picture, noting that the broader alcohol industry, including Constellation, has struggled recently, facing challenges such as decreased sales driven by ICE raids in key shopping areas. This year, the stock has experienced a significant decline of 36%, with its current price-to-earnings ratio at a notably low 12x. While some view this low valuation as attractive, it is deemed justified due to ongoing weak sales and the emergence of competition from GLP-1 drugs. Overall, while there are signs of potential recovery, significant headwinds linger for Constellation Brands.
Last week, it reported stellar numbers but shares still fell, a victim to persistent misconceptions. Their Modelo is the #1 beer in the US and is gaining market share. Pacifico sales are up 21%. STZ operating margins were up 260 basis points. They beat Q1 EPS. Shares should be selling at $300. The problem is STZ also sells hard liquor, which Wall Street has given up on as well as doubts that beer's popularity is waning. Has huge free cash flow, are buying back shares, and is expanding facilities. Other threats are the weight-loss drugs and the popularity of cannabis. He won't abandon this stock though.
He's long owned this, but the stock has hit several road blocks including a bad investment in cannabis-maker Canopy Growth and the company founders selling huge amounts of shares. he's stuck with it, because he believes in their Mexican beers like Modelo. They just reported solid numbers, like an earnings beat, and a sunny forecast about beer sales even wine/spirits isn't doing as well. Is a long way from last year's highs, but is undervalued.
Stock has been sinking for months and faces concerns of the eight-loss drugs impacted their beer sales.